SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Drug Delivery: Top Headlines

Magnetically controlled drug dissolves blood clots with fewer side effects

The influence of developed thrombolytic system on vascular thrombus extracted during the operation. (Image: ITMO University)

27-Jun-2016 - Researchers have developed a new magnetically controlled drug that can dissolve clots up to 4,000 times more efficiently than ordinary enzyme-based drugs.

Related news

News in brief

Collegium's OxyContin rival is first drug using Deterx anti-abuse tech launched in US

21-Jun-2016 - Collegium Pharmaceutical has launched the first product formulated using its Deterx anti-abuse technology in the US.

Dispatches from BIO 2016

Drug development in space: how microgravity enables pharma

15-Jun-2016 - Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the next year – with several implications for pharma back on Earth.

Replicating DNA structures is key to faster gene therapy vector manufacturing says Touchlight

10-Jun-2016 - Replicating secondary structures in viral DNA could by key to developing to faster AAV vector production methods according to Touchlight.

update

Cobra and Touchlight aim to make AAV vector production faster and cheaper

07-Jun-2016 - Cobra Biologics has teamed up with Touchlight to test an AAV vector production platform they claim will make manufacturing gene therapies for trials cheaper and faster.

US FDA approved implant offers opioid addicts six-months continuous treatment

02-Jun-2016 - The US FDA has approved Probuphine, a subdermal buprenorphine treatment for opioid dependence using Titan Pharmaceuticals’ ProNeura drug delivery platform.

EU approves second indication for subcutaneous form of Roche's rituximab

01-Jun-2016 - Roche’s subcutaneous formulation of MabThera is about reducing the treatment burden for patients and not protecting it from impending biosimilar competition, the firm says.

Novo Nordisk and Sanofi diabetes combo drugs receive US recommendation

26-May-2016 - The US FDA has voted in favour of two combination type 2 diabetes drugs putting Novo Nordisk and Sanofi head-to-head in a crowded market.

Drug Delivery: Featured news

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...